LandmarkRCT

Tan HFNC versus NIV

High flow nasal cannula oxygen therapy versus non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled non-inferiority trial.

Crit Care, 2024 · Open-label noninferiority trial at two ICUs within one center

Population: 225 analyzed adults with AECOPD, pH 7.25–7.35 and PaCO2 ≥50 mmHg
Intervention: HFNC as initial support
Comparator: NIV
Primary outcome: Treatment failure: intubation or switch of support
Result: Failure 25.7% versus 14.3%; intubation 14.2% versus 5.4%. HFNC did not meet the noninferiority criterion.

What the trial found

Failure 25.7% versus 14.3%; intubation 14.2% versus 5.4%. HFNC did not meet the noninferiority criterion.

Clinical interpretation

Supports NIV as default in acidotic AECOPD. ATS 2026 permits selected mild-acidemia HFNC use with close monitoring and prompt NIV escalation; the trial does not prove mortality superiority.

Limitations

Single-center, open-label; composite includes treatment switching.

Moderate certainty

Clinical Context & Relevant Topics (2)

Disease Reference

COPD Exacerbation (Acute & Severe)

Pathophysiology of acute-on-chronic hypercapnia, controlled oxygen targets (88–92%), evidence-based NIV, and auto-PEEP matching mechanics.

View Topic Context →

Hypercapnic Respiratory Failure

Mechanism-based diagnosis of acute and acute-on-chronic hypercapnia, controlled oxygen, NIV, invasive ventilation, auto-PEEP troubleshooting, neuromuscular monitoring, and post-acute planning.

View Topic Context →